Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Marea Therapeutics said Wednesday that an experimental drug reduced by half a type of blood fat called remnant cholesterol — a mid-stage study result that paves the way for further trials and could lead to a new way of treating cardiovascular disease. 

Remnant cholesterol is distinct from LDL (bad) or HDL (good) cholesterol, and elevated levels are associated with a higher risk of serious cardiovascular events even in patients prescribed standard cholesterol-lowering medicines, said Ethan Weiss, Marea’s co-founder and chief scientific officer. 

No drugs currently approved lower remnant cholesterol.